References
- Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–1481. DOI:10.1183/09031936.00218714
- Satia I, Mayhew AJ, Sohel N, et al. Prevalence, incidence and characteristics of chronic cough among adults from the canadian longitudinal study on aging. ERJ Open Res. 2021;7(2):00160–02021. DOI:10.1183/23120541.00160-2021
- Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339–343. DOI:10.1136/thorax.58.4.339
- French CL, Irwin RS, Curley FJ, et al. Impact of chronic cough on quality of life. Arch Intern Med. 1998;158(15):1657. Available from: https://pubmed.ncbi.nlm.nih.gov/9701100/
- Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):55. DOI:10.1183/13993003.01136-2019
- Satia I, Wahab M, Kum E, et al. Chronic cough: investigations, management, current and future treatments. Can J Respir Crit Care Sleep Med. 2021;5(6):404–416. Available from: https://www.tandfonline.com/doi/abs/10.1080/24745332.2021.1979904
- Shim J, Brindle L, Simon M, et al. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137–148. DOI:10.1093/fampra/cmt076
- Satia I, Mayhew AJ, Sohel N, et al. Impact of mental health and personality traits on the incidence of chronic cough in the canadian longitudinal study on aging. ERJ Open Res. [cited 2023 Feb 2]. 2022;8:00119–2022. Available from. 2. https://pubmed.ncbi.nlm.nih.gov/35651367/
- Dicpinigaitis P v., SS B, Blaiss M, et al. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Annals of Allergy, Asthma & Immunol. [cited 2023 Feb 2]. 2023;130:60–66. Available from. 1. https://pubmed.ncbi.nlm.nih.gov/35569802/
- Smith JA, Satia I, Badri H, et al. Mini-review: hypertussivity and allotussivity in chronic cough endotypes. Neurosci Lett. 2023;792:136934. DOI:10.1016/j.neulet.2022.136934
- Johansson H, Johannessen A, Holm M, et al. Prevalence, progression and impact of chronic cough on employment in Northern Europe. Eur Respir J. [cited 2023 Feb 2]. 2021;57:2003344. Available from. 6. https://pubmed.ncbi.nlm.nih.gov/33303532/
- Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018;15(3):348–356. Available from: https://pubmed.ncbi.nlm.nih.gov/29323930/
- Brightling CE, Ward R, Goh KL, et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med. 1999;160(2):406–410. Available from: https://pubmed.ncbi.nlm.nih.gov/10430705/
- Turcotte SE, Lougheed MD. Cough in asthma. Curr Opin Pharmacol. 2011;11(3):231–237. Available from: https://pubmed.ncbi.nlm.nih.gov/21565551/
- Chamberlain Mitchell SAF, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017;72:129–136.
- Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8:775–785.
- McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399:909–923.
- Palombini BC, Villanova CAC, Araújo E, et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest. 1999;116:279–284. Available from https://pubmed.ncbi.nlm.nih.gov/10453852/
- Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis. 1990;141:640–647. Available from. https://pubmed.ncbi.nlm.nih.gov/2178528/
- Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014;44:1132–1148. Available from https://pubmed.ncbi.nlm.nih.gov/25142479/
- Javorkova N, Varechova S, Pecova R, et al. Acidification of the oesophagus acutely increases the cough sensitivity in patients with gastro-oesophageal reflux and chronic cough. Neurogastroenterol Motil. 2008 [[cited 2023 Feb 16]];20:119–124. Available from https://pubmed.ncbi.nlm.nih.gov/17999650/
- Tatar M, Plevkova J, Brozmanova M, et al. Mechanisms of the cough associated with rhinosinusitis. Pulm Pharmacol Ther. 2009 [[cited 2023 Feb 16]];22:121–126. Available from https://pubmed.ncbi.nlm.nih.gov/19111626/
- Hennel M, Brozmanova M, Kollarik M. Cough reflex sensitization from esophagus and nose. Pulm Pharmacol Ther. 2015;35:117–121.
- Satia I, Nagashima A, Usmani OS. Exploring the role of nerves in asthma; insights from the study of cough. Biochem Pharmacol. 2020;179(Sep):113901.
- Satia I, Watson R, Scime T, et al. Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. J Allergy Clin Immunol. 2019;144:788–795.e1.
- Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: aCCP evidence-based clinical practice guidelines. Chest. 2006;129:1S–23S. Available from https://pubmed.ncbi.nlm.nih.gov/16428686/
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022;205:17–35. Available from https://pubmed.ncbi.nlm.nih.gov/34658302/
- Chaudhuri R, McMahon AD, Thomson LJ, et al. Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. J Allergy Clin Immunol. 2004;113:1063–1070.
- Boulet LP, Milot J, Boutet M, et al. Airway inflammation in nonasthmatic subjects with chronic cough. Am J Respir Crit Care Med. 1994;149:482–489. Available from https://pubmed.ncbi.nlm.nih.gov/8306050/
- Pizzichini MMM, Pizzichini E, Parameswaran K, et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. Can Respir J. 1999;6:323–330. Available from https://pubmed.ncbi.nlm.nih.gov/10463960/
- Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Annals of Allergy, Asthma & Immunol. 2004;93:232–236. Available from. https://pubmed.ncbi.nlm.nih.gov/15478381/
- Matera MG, Rogliani P, Zanasi A, et al. Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther. 2017;47:88–92. Available from https://pubmed.ncbi.nlm.nih.gov/28527922/
- Becker LA, Hom J, Villasis-Keever M, et al. Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. Cochrane Database Syst Rev. 2015; p. 2015. Available from: https://pubmed.ncbi.nlm.nih.gov/26333656/
- Dicpinigaitis PV, JB D, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma. 2002;39:291–297. Available from. https://pubmed.ncbi.nlm.nih.gov/12095178/
- Kita T, Fujimura M, Ogawa H, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int. 2010;59:185–192. Available from https://pubmed.ncbi.nlm.nih.gov/20299826/
- Smith JA, McGarvey L, Morice AH, et al. The effect of aclidinium on symptoms including cough in chronic obstructive pulmonary disease: a phase 4, double-blind, placebo-controlled, parallel-group study. Am J Respir Crit Care Med. 2019;200:642–645. Available from https://pmc/articles/PMC6727161/
- Fletcher KE, French CT, Irwin RS, et al. A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. J Clin Epidemiol. 2010 [cited 2023 Jan 31];63:1123–1131. Available from https://pubmed.ncbi.nlm.nih.gov/20303709/
- Ogawa H, Fujimura M, Takeuchi Y, et al. The importance of basidiomycetous fungi cultured from the sputum of chronic idiopathic cough: a study to determine the existence of recognizable clinical patterns to distinguish CIC from non-CIC. Respir med. 2009 [[cited 2023 Jan 31]];103:1492–1497. Available from https://pubmed.ncbi.nlm.nih.gov/19473825/
- Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27–56. Available from https://pubmed.ncbi.nlm.nih.gov/34807007/
- Kahrilas PJ, Altman KW, Chang AB, et al. Chronic cough due to gastroesophageal reflux in adults: chest guideline and expert panel report. Chest. 2016;150:1341–1360. Available from https://pubmed.ncbi.nlm.nih.gov/27614002/
- Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017;5:806–815. Available from https://pubmed.ncbi.nlm.nih.gov/28923239/
- Vertigan AE, Theodoros DG, Gibson PG, et al. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax. 2006;61:1065–1069.
- Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175:312–315.
- Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;10. Available from https://pubmed.ncbi.nlm.nih.gov/29084357/
- Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:1583–1589.
- Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016;149:639–648.
- Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006;116:2108–2112. Available from. https://pubmed.ncbi.nlm.nih.gov/17146380/
- Badri H, Gibbard C, Denton D, et al. A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough. ERJ Open Res. 2022 [[cited 2023 Mar 22]];8. Available from: https://pubmed.ncbi.nlm.nih.gov/35295236/
- Dicpinigaitis PV, JB D, Rauf K, et al. Inhibition of capsaicin-induced cough by the gamma-aminobutyric acid agonist baclofen. J Clin Pharmacol. 1998;38:364–367. Available from https://pubmed.ncbi.nlm.nih.gov/9590464/
- Mazzone SB, Undem BJ. Vagal afferent innervation of the airways in health and disease. Physiol Rev. 2016;96:975–1024. Available from. https://pubmed.ncbi.nlm.nih.gov/27279650/
- Undem BJ, Chuaychoo B, Lee MG, et al. Subtypes of vagal afferent C-fibres in guinea-pig lungs. J Physiol. 2004;556:905. Available from https://pmc/articles/PMC1665007/
- Canning BJ. Afferent nerves regulating the cough reflex: mechanisms and Mediators of Cough in Disease. Otolaryngol Clin North Am. 2010;43:15. Available from. https://pmc/articles/PMC2882535/
- Birrell MA, Belvisi MG, Grace M, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med. 2009;180:1042. Available from https://pmc/articles/PMC2784411/
- Ando A, Smallwood D, McMahon M, et al. Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016;71:323–329.
- Abubakar AB, Bautista TG, Dimmock MR, et al. Behavioral and regional brain responses to inhalation of capsaicin modified by painful conditioning in humans. Chest. 2021;159:1136–1146. Available from https://pubmed.ncbi.nlm.nih.gov/32926869/
- Hilton E, Satia I, Holt K, et al. The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough. Eur Respir J. 2020;56(6):2001387.
- Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385:1198–1205. Available from https://pubmed.ncbi.nlm.nih.gov/25467586/
- Smith JA, Kitt MM, Butera P, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55. Available from https://pubmed.ncbi.nlm.nih.gov/31949115/
- Merck Provides U.S. and Japan Regulatory Update for Gefapixant - Merck.Com. Available from: https://www.merck.com/news/merck-provides-u-s-and-japan-regulatory-update-for-gefapixant/.
- Birring SS, Smith JA, Mcgarvey L, et al. Efficacy in SOOTHE, a Phase 2b Trial of BLU-5937 in refractory chronic cough, was not dependant of taste disturbance adverse events. Eur Respir J. 2022;60:807.
- Martinez FJ, Afzal AS, Smith JA, et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther. 2021;7:471–486.
- Bayer will discontinue phase II development candidate eliapixant. Available from: https://www.bayer.com/media/en-us/bayer-will-discontinue-phase-ii-development-candidate-eliapixant/.
- A 52-week study of the efficacy and safety of BLU-5937 in adults with refractory chronic cough - full text view - ClinicalTrials.Gov.
- Niimi A, Saito J, Kamei T, et al. Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough. Eur Respir J. 2022 [[cited 2023 Jan 22]];59. Available from: https://pubmed.ncbi.nlm.nih.gov/34649978/
- McGarvey L, Smith JA, Morice A, et al. A randomized, double-blind, placebo-controlled, parallel-group phase 2b Trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough. Lung. 2022 [cited 2023 Jan 22];p. 1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36512069.
- Buday T, Kovacikova L, Ruzinak R, et al. TRPV4 antagonist GSK2193874 does not modulate cough response to osmotic stimuli. Respir Physiol Neurobiol. 2017;236:1–4. Available from https://pubmed.ncbi.nlm.nih.gov/27989888/
- Belvisi MG, Birrell MA, Wortley MA, et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017;196:1255–1263.
- Khalid S, Murdoch R, Newlands A, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134. Available from https://pubmed.ncbi.nlm.nih.gov/24666696/
- A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic effects of GDC-6599 in patients with chronic cough - full text view - ClinicalTrials.Gov. [cited 2023 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT05660850?term=GA43590&draw=2&rank=1.
- Bautista DM, Siemens J, Glazer JM, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature. 2007 [[cited 2023 Feb 8]];448448:7150–208204–208. Available from https://www.nature.com/articles/nature05910
- Axalbion announces positive findings from phase 2 Study. [cited 2023 Feb 8]. Available from: https://axalbion.com/2022/06/29/axalbion-announces-positive/.
- Abdulqawi R, Satia I, Kanemitsu Y, et al. A randomized controlled trial to assess the effect of lidocaine administered via throat spray and nebulization in patients with refractory chronic cough. J Allergy Clin Immunol Pract. 2021 [[cited 2023 Feb 8]];9:1640–1647. Available from https://pubmed.ncbi.nlm.nih.gov/33259976/
- Placebo-controlled, single and multiple dose study in healthy volunteers and refractory chronic cough patients to assess the safety, tolerability, and pharmacokinetics of two formulations of NTX-1175 - full text view - ClinicalTrials.Gov
- Smith J, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest. 2020;157:111–118. Available from https://pubmed.ncbi.nlm.nih.gov/31421110/
- A dose-ranging study of orvepitant in patients with chronic refractory cough - study results - ClinicalTrials.Gov.
- Smith J, Ballantyne E, Kerr M, et al. The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial. nerretherapeutics com. 2003;58:1198–1205. Available from: https://www.conf-name.nerretherapeutics.com/wp-content/uploads/2019/09/ers-2019-poster.pdf
- Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT05185089.
- Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough - Study Results - ClinicalTrials.gov [Internet]. [cited 2023 Jan 29]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03282591?term=Serlopitant&cond=cough&draw=2&rank=1
- Smith JA, Harle A, Dockry R, et al. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. Am J Respir Crit Care Med. 2021 [[cited 2023 Jan 22]];203:737–745. Available from https://pubmed.ncbi.nlm.nih.gov/32966755/
- Chaffey H, Chazot PL. NMDA receptor subtypes: Structure, function and therapeutics. Curr Anaesth Crit Care. 2008;19:183–201.
- Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293–299. Available from. https://pubmed.ncbi.nlm.nih.gov/1828878/
- Pavesi L, Subburaj S, Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest. 2001;120:1121–1128. Available from. https://pubmed.ncbi.nlm.nih.gov/11591548/
- Smith JA, Hilton ECY, Saulsberry L, et al. Antitussive effects of memantine in guinea pigs. Chest. 2012;141:996–1002. Available from https://pubmed.ncbi.nlm.nih.gov/22016492/
- Abdulqawi R, Satia I, Holt KJ, et al. An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. ERJ Open Res. 2021;7. Available from https://pmc/articles/PMC8450582/
- Algernon Pharmaceuticals Hits Co-Primary Endpoint in its endpoint. Available from: https://www.globenewswire.com/news-release/2022/07/18/2481017/0/en/Algernon-Pharmaceuticals-Hits-Co-Primary-Endpoint-in-its-Phase-2-Study-of-Ifenprodil-for-Idiopathic-Pulmonary-Fibrosis-and-Chronic-Cough.html
- Molyneaux P, Forbes W, Bortey E, et al. S15 Efficacy of oral nalbuphine extended release for the treatment of chronic cough in idiopathic pulmonary fibrosis: analysis of a phase 2 study. Thorax. 2022;77:A13–14.
- Morice AH, Kitt MM, Ford AP, et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J. 2019;54:9.
- McGarvey L, Smith JA, Morice A, et al. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung. 2023;201(1):25–35. DOI:10.1007/s00408-022-00592-5